Biopure To Develop Hemopure As Cardioprotective Agent Under Restructuring
This article was originally published in The Pink Sheet Daily
Executive Summary
The company has established a cardiology medical advisory board under the direction of new CEO Zafiris Zafirelis. Biopure expects that data from FDA-requested animal studies will allow it to move forward with U.S. clinical trials for cardiac ischemia.
You may also be interested in...
Biopure Submits Hemopure Application In The U.K.
The company says it targeted the United Kingdom before the rest of the EU because of the country's "unique blood banking issues."
U.S. Patents Could Limit President's AIDS Drug Assistance Plan, GAO Says
The U.S. Global AIDS Coordinator's Office suggests it will use its authority to purchase an FDA-approved generic antiretroviral product for which permission could not be obtained from the patent holder. FDA grants tentative approval to a South African firm for a generic co-packaged version of Combivir and Viramune.